Peptides DB
Research-centric peptide and protocol reference hub

Ecnoglutide record · updated 6h ago

Metabolic & appetiteNeuro & moodGrade A · human clinicalResearch use only
All 5 studiesJump to the evidenceCompare
What is Ecnoglutide used for?

Research peptide discovered via AI researcher. research peptide

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetite

Development stage

where Ecnoglutide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Current
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 39 registered trials. It describes the research record, not a recommendation.

Identity
NameEcnoglutide
Chain length—
Molecular weight4,285 Da
FormulaC194H304N48O61
Structure typeNot established
ClassMetabolic
Research levelWell Studied
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 162625103. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 receptor agonist
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 7, 2026. How this works →
Research stats
Total studies5
Human / animal / cellular1 / 1 / 0
Highest trial phasePhase 1
Years covered2025–2026
Latest study15d ago
Publication history
20252026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

5 rowsOpen in the library →
StudyTypeYearSummary depth
<i>Escherichia coli</i> outer membrane vesicles: Bacterial virulence, antibiotic resistance, host interactions, and applications in biomedical platforms.
TakeawayE. coli OMVs are crucial in bacterial virulence and resistance, with potential applications in biomedical fields like vaccine development.
review2026Full text read0.90
Genome-integrated engineering of <i>Escherichia coli</i> Nissle 1917 enables sustained gut-local biosynthesis of 5-hydroxytryptophan.
Finding5-HTP titer of 863.2 mg/L, the highest level reported in EcN-based systems.
Animal2026Full text read0.70
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Finding-1.96% HbA1c vs placebo at 24 wk with 0.6 mg ecnoglutide, n=69.
Human2025Full text read0.80
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update.
TakeawayNot reported in abstract.
—2026Title only0.10
Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.
TakeawayNot reported in abstract.
—2026Title only0.10

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Ecnoglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Ecnoglutide is discussed should be drawn from it.